Corcept Therapeutics Shares Slide Premarket on Loss in Teva Patent Suit
By Colin Kellaher
Shares of Corcept Therapeutics tumbled more than 30% in premarket trading Tuesday after the pharmaceutical company suffered a setback in its patent-infringement litigation against generic drugmaker Teva Pharmaceuticals.
A U.S. District Court judge in New Jersey late Friday ruled that Teva's planned generic version of Corcept's Korlym drug for Cushing's syndrome didn't infringe Corcept's patents.
Corcept, based in Menlo Park, Calif., on Tuesday said it plans to appeal the ruling, which it said is "based on legal and factual errors."
Corcept filed patent-infringement litigation against Teva in 2018, shortly after Teva sought U.S. Food and Drug Administration approval for its generic version of Korlym.
The FDA approved Teva's generic version in 2020, and Corcept has said in previous filings with the Securities and Exchange Commission that Teva can opt to begin marketing its generic product at any time, notwithstanding the ongoing litigation.
Corcept shares, which closed Friday at $32.48, were recently down nearly 33% to $21.90 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 02, 2024 08:35 ET (13:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters